Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 6/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4980906 | 0.93 | KDR (0.42) | KDRSLC2A1METROCK2 | |
| SCHEMBL4977121 | 0.92 | KDR (0.47) | KDRSLC2A1METROCK2 | |
| SCHEMBL4980382 | 0.92 | KDR (0.43) | KDRSLC2A1METROCK2 | |
| SCHEMBL4976599 | 0.91 | SLC2A1 (0.41) | KDRSLC2A1METROCK2 | |
| SCHEMBL4978436 | 0.90 | ROCK2 (0.43) | KDRSLC2A1ROCK2 | |
| SCHEMBL4979259 | 0.89 | KDR (0.42) | KDRSLC2A1METROCK2RORC | |
| SCHEMBL4978778 | 0.89 | SLC2A1 (0.43) | KDRSLC2A1METROCK2RORC | |
| SCHEMBL4980536 | 0.89 | SLC2A1 (0.43) | KDRSLC2A1METROCK2 | |
| SCHEMBL4978451 | 0.89 | KDM4E (0.45) | KDRMETROCK2 | |
| SCHEMBL4979918 | 0.88 | KDR (0.44) | KDRMETRETPDGFRAFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7338959-B2 | Diamino-pyrimidines and their use as angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-03-04 | — | — | US | claimed |
| US-20050234083-A1 | Diamino-pyrimidines and their use as angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-10-20 | — | — | US | claimed |
| US-7338959-B2 | Diamino-pyrimidines and their use as angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-20050234083-A1 | Diamino-pyrimidines and their use as angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-10-20 | — | — | US | disclosed |
| EP-1487824-A1 | DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003074515-A1 | DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234083-A1 | Diamino-pyrimidines and their use as angiogenesis inhibitors | TIE1, TEK, KDR | KDR 3/4885SLC2A1 2444/4885MET 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.